In the phase II clinical trial, the safety and efficacy of simvastatin combined with cetuximab were evaluated in metastatic CRC patients with KRAS mutations who had previously received fluoropyrimidine, oxaliplatin, and irinotecan-based treatment regimens. The gene discussed is KRAS; the disease is colorectal carcinoma.